 |
Fourth International Symposium on Resistant Gram-Positive Infections |
||||
|
|
Abstracts from the Third International Symposium on Resistant Gram-Positive Infections in 2006 are listed below. (Click on title to read abstract.) |
 |
||||
|
|
||||||
|
CPLA
#1:Clostridium difficile Antibody Titers Prior to and Following IVIG for
Relapsing Colitis. Authors: *Lawrence A. Cone,1,2 Michael S. Somero,1 Radhika Gade-Andavolu2. Affiliations: 1Eisenhower Medical Center: 2 Genetic Research
Institute of the Desert, Rancho Mirage, CA, USA
Authors: *Jeremias L Murillo,1 Pat
Harmon,1 Wilfredo Cruz,1 Trini Chan,1 Morris Cohen,1 Madhavi Koraboina,2 Barry
Kreiswirth,2 Affiliations: 1 Newark Beth Israel Medical Center, Newark, NJ;
2 Public Health Research Institute, Newark, NJ.
CPLA #3: In vitro Susceptibility of Streptococcus pneumoniae to
Ceftobiprole and Comparative b-Lactams.
Authors: Peter C. Appelbaum,1 *Todd A. Davies,2 Karen
Bush,2 Lois M. Ednie,1 Tatiana Bogdanovich,1 Klaudia Kosowska1 Affiliations: 1 Hershey
Medical Center, Hershey, PA; 2 Johnson & Johnson Pharm. Res. & Dev.,
Raritan, NJ. Authors: *Michael R. Jacobs, Caryn Good, Saralee
Bajaksouzian, Anne Windau, Affiliations: Case
Western Reserve University and University Hospitals of Cleveland, Cleveland, OH.
CPLA #5: Activity of Ceftobiprole against Methicillin
Susceptible and Resistant Staphylococci.
Authors: *Michael R. Jacobs,1 Karen Amsler,2 Saralee
Bajaksouzian,1 Anne Windau,1 Lois M. Ednie,3 Tatiana Bogdanovich,3 Peter C.
Appelbaum.3 Affiliations: 1
Case
Western Reserve University and University Hospitals of Cleveland, Cleveland, OH;
2 Johnson & Johnson Pharm. Res. & Dev., Raritan, NJ; 3 Hershey Medical
Center, Hershey, PA. CPLA #6: Successful Treatment of Chronic MRSA Sinusitis with Daptomycin. Authors: George
B Baxter,1 Affiliations: 1.University
of South Alabama, Mobile, AL; 2.Danville Regional Medical Center, Danville, VA;
3.Brody School of Medicine at East Carolina University, Greenville, NC.
CPLA
#7: Characterization of Mupirocin Resistance in MRSA from Saskatchewan. Authors: *Christine
G Siemens1, Ryan McDonald2, Paul Levett2, Greg Horsman2, Mohammad Khan3, Mandiangu Nsungu4, James Irvine5, Michael R. Mulvey1,6, and the Northern
Antimicrobial Resistance Partnership Affiliations:
1.University of Manitoba, Winnipeg, MB; 2.Provincial Laboratory, Saskatchewan
Health, Regina, SK.; 3.Kelsey Trail Health Region, Melfort, SK.;
4.Northern Intertribal Health Authority, SK.; 5.Keewatin-Yatthe Regional Health
Authority, SK;
6.National Microbiology Laboratory, Winnipeg, MB.
Authors: *Christine G Siemens1, George R Golding1, Michael R.
Mulvey1,2, and the Canadian Nosocomial Infection Surveillance Program Affiliations:
1.University of Manitoba, Winnipeg, MB, Can. 2.Public Health Agency of Canada,
Winnipeg, MB, Can. Authors: *Jennifer L. Campbell1, David Spreitzer1,
Christine Watt2, Andrew. E. Simor2, Marianna Ofner3, Denise Gravel3, Shirley
Paton3, Allison McGeer4, Mark Loeb5, Elizabeth. Bbryce6, Ann Matlow7, Michael R.
Mulvey1 and The Canadian Nosocomial Infection Surveillance Program. Affiliations: 1National
Microbiology Laboratory, Winnipeg, MB, 2Sunnybrook Health Sciences Centre,
Toronto, ON, 3The Division of Nosocomial Infection and Occupational Infections,
Ottawa, ON, 4Mount Sinai Hospital, Toronto, ON, 5McMaster University, Hamilton,
ON, 6Vancouver General Hospital, Vancouver, BC, 7Hospital for Sick Children,
Toronto, ON.
CPLA #10: Microbiological Activity of Ceftobiprole Against Enterococci.
Authors: C.A. Arias, K. V. Singh, *B. E. Murray.
Affiliations: Univ. of Texas Health Ctr., Houston, TX.
CPLA #11: Pharmacokinetic
Modeling of Telavancin Penetration into Skin Blister
Fluid. Authors: *Shekman L. Wong,1 Jeng-Pyng Shaw,1 David P. Nicolau,2 Steven L. Barriere,1
Michael M. Kitt,1 Michael R.
Goldberg.1 Affiliations: 1.Theravance,
Inc., South San Francisco, CA, USA; 2.Center for Anti-Infective Research and
Development, Hartford Hospital, Hartford, CT, USA. Authors: Maritza Barcia-Macay, Sandrine Lemaire,
Marie-Paule Mingeot-Leclercq, *Paul M. Tulkens, Françoise Van Bambeke. . Affiliations: Université Catholique de Louvain, Brussels,
Belgium.
CPLA
#13: Evidence
for a Multivalent Interaction between Telavancin and Membrane-Bound Lipid II.
Authors:
*Eefjan
J. Breukink,1 Inge Visscher,1 Patrick P. A. Humphrey2,
Bret M. Benton.2,1. Affiliations:
1Utrecht
University, Utrecht, The Netherlands; 2.Theravance, Inc., South San Francisco,
CA, USA.
CPLA#14:
Telavancin Is Efficacious in a Murine
Model of Staphylococcal Pneumonia.
Authors:
*Sharath S. Hegde, Noe Reyes, Robert Skinner. Affiliations:
Theravance, Inc., South San Francisco, CA, USA. Authors: *Marika Renelli, Christopher J. Linnevers, Patrick
P. A. Humphrey, Mathai Mammen, Bret M. Benton. Affiliations: Theravance, Inc., South San Francisco, CA, USA. Authors: *Daniel F. Sahm,1 Bret
M. Benton,2 Michael A. Cohen,1 Mark E. Jones,3 Kevin M. Krause,1 Clyde
Thornsberry,1 Deborah C. Draghi.1 Affiliations: 1.Focus Bio-Inova, Inc.,
Herndon, VA, USA; 2.Theravance, Inc., South San Francisco, CA, USA;
3.Focus Bio-Inova,
Inc., Plaisir, France.
CPLA
#17: Effects
of Human Serum on In Vitro Activity of Telavancin.
Authors: *Patrick
F. Smith, Brian T. Tsuji, Pamela Kelchin, Olanrewaju
O. Okusanya, Alan Forrest. Affiliations:
State University of New York at Buffalo, Buffalo, NY, USA. Authors: *Shekman L. Wong,1.Jeng-Pyng Shaw,1.Mark
H. Gotfried,2.Steven
L. Barriere,1. Michael M. Kitt,1.Michael
R. Goldberg.1 Affiliations: 1.Theravance, Inc., South
San Francisco, CA, USA; 2.Pulmonary Associates, Phoenix, AZ, USA. Authors: *Deborah
C. Draghi,1 Bret M. Benton,2 Michael
A. Cohen,1 Mark E. Jones,3 Kevin M. Krause,2 Clyde Thornsberry,1 Daniel F.
Sahm.1 Affiliations: 1.Focus Bio-Inova, Inc.,
Herndon, VA, USA;2.Theravance, Inc., South San Francisco, CA, USA;3.Focus Bio-Inova,
Inc., Plaisir, France. Authors: *B
Keith English1,2, Erik M Maryniw1,2, Ajay J Talati1,2 and Elizabeth A Meals1,2. Affiliations: 1Children's Foundation Research Center at Le Bonheur Children's Medical
Center and 2University of Tennessee Health Science Center, Memphis, TN 38103. Authors: J. M. Blondeau¹, S.D.
Borsos2. Affiliations:
1.Department
of Clinical Microbiology, Royal University Hospital, Department of Microbiology
and Immunology, Department of Pathology, University of Saskatchewan, Saskatoon,
SK, Canada. 2.Department of Clinical
Microbiology, Royal University Hospital, Saskatoon, SK, Canada Authors:
Morrissey, I1, File Jr., TM2 and Mandell, LA3.
Affiliations:
1GR
Micro Ltd., London, UK., 2Summa Health System, Akron, OH, USA, 3 McMaster
University, Hamilton, Canada,4 Authors: KL LaPlante1, MJ Rybak1,2
BT Tsuji1, GW Kaatz1,2,3 Affiliations: Authors: R. Reynolds, D.
Felmingham, BSAC Working Party on Respiratory Resistance Surveillance Affiliations: British
Society for Antimicrobial Chemotherapy (BSAC), Birmingham, UK; GR Micro Ltd.,
London, UK. Authors: J. M. Blondeau¹, S.D. Borsos2. Affiliations: 1.Department of Clinical
Microbiology, Royal University Hospital, Department of Microbiology and
Immunology, Department of Pathology, University of Saskatchewan, Saskatoon, SK,
Canada. 2.Department of Clinical Microbiology, Royal University Hospital,
Saskatoon, SK, Canada Authors: *Jack Brown,
Kenneth C. Lamp, Lawrence V. Friedrich. Affiliations: Cubist Pharmaceuticals, Lexington, MA
CPLA
#28:
Effect of Thymidine on the Activity of
Diaminopyrimidine Antibacterial Agents Authors: Stephen Hawser, Muriel
Bihr, Laurent Weiss, Khalid Islam and *Sergio Lociuro Affiliations: Arpida AG, Switzerland. Authors:*Paul
Hadvary1,Jenny Andrews2, David Honeybourne 3, Janet Ashby2,
Gail Jevons2, Adam Fraise2, Patricia Fry4,
Richard Wise2; Affiliations:1Arpida
AG, Switzerland, 2City Hosp., Birmingham, United Kingdom, 3Heartlands
Hosp., Birmingham, United Kingdom, 4Hammersmith Med. Res. Limited,
London, United Kingdom Authors:*Stephen
Hawser1, Jose Entenza2, Marlyse Giddey2,
Jacques Vouillamoz2, Phillippe Moreillon2 and Khalid Islam1 Affiliations:1Arpida AG, Switzerland and 2University
of Lausanne, Switzerland Authors: Dainis Krievens 1, Anton
Leighton2, Roger Brandt 2, *Paul Hadvary 2,
Stephen Hawser2, Dieter Gillessen 2 and Khalid Islam2;
1Stradini Affiliations: Clinical Univ. Hosp., Riga, Latvia, 2Arpida
AG, Switzerland. Authors:
*Stephen Hawser, Sergio Lociuro, Khalid Islam Affiliations: Arpida AG,
Switzerland Authors:
Roger Brandt1, Stuart Irons2, Alan McBurney2,
Virginia Norris2, Steve Warrington3 Torben Thomsen4,
*Paul Hadvary1 and Khalid Islam1 Affiliations:1
Arpida AG, Switzerland, 2Huntingdon Life
Sciences Ltd, England, 3Hammersmith Medicines Research, England, 4Pharma
PlanNet Contract Research GmbH, Germany, Authors:*Stephen
Hawser, Sergio Lociuro, Khalid Islam Affiliations: Arpida
AG, Switzerland |
||||||
|
|
||||||